Analysts are intrested in these 5 stocks: ( (AQN) ), ( (SPOT) ), ( (KEYS) ), ( (NTLA) ) and ( (CRWV) ). Here is a breakdown of their recent ratings and the rationale behind them.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Algonquin Power & Utilities is catching the attention of investors with a recent upgrade from analyst Michael Gaugler, who has moved the stock from Neutral to Buy. The upgrade comes on the back of strong quarterly results and improved fundamentals, with a new fair value estimate set at $7.00. Algonquin’s regulated services group showed impressive earnings growth, and the company is making significant strides in its regulatory rate case agenda. With a new CFO set to join in January 2026, the company maintains its guidance, signaling stability and potential for future growth.
Spotify is making waves with its strong pricing power, leading analyst Helena Wang to upgrade the stock to Buy. Despite recent price increases across multiple markets, Spotify continues to see robust growth in premium subscribers and monthly active users, surpassing guidance. The company’s integration with ChatGPT and enhancements to its free tier are expected to boost user engagement and conversion rates. Spotify’s ability to maintain growth amidst price hikes highlights its market strength and positions it well for future revenue stability.
Keysight Technologies is gaining momentum with analysts Andrew Spinola and Atif Malik both initiating coverage with a Buy rating. The company is positioned at an inflection point, driven by strong demand for AI infrastructure and synergies from recent acquisitions. Keysight’s focus on AI and data center demand is expected to accelerate growth, with a target price set at $220. The company’s strategic acquisitions and pricing actions are anticipated to bolster earnings growth, making it an attractive investment opportunity.
Intellia Therapeutics faces a challenging path as analysts Jonathan Miller, Debanjana Chatterjee, and Andy Chen downgrade the stock to Hold. The company is grappling with safety concerns following a severe liver toxicity event in its ATTR-CM program. While recent data shows strong efficacy, the clinical hold and safety risks have cast a shadow over the stock. Intellia’s HAE program offers some hope, but the market remains cautious given the competitive landscape and safety issues.
CoreWeave is experiencing a mixed reception as analyst Mark Murphy downgrades the stock to Hold, while Michael Donovan initiates coverage with a Buy rating. The company’s backlog has skyrocketed, driven by strong demand for AI infrastructure, but supply chain pressures are causing concerns. CoreWeave’s ability to secure long-term contracts with major clients like Microsoft and OpenAI underscores its potential, yet the supply chain challenges and revenue timing issues are prompting a more cautious outlook. Despite these hurdles, CoreWeave’s position in the AI market remains strong, with a promising future ahead.